Ardelyx, Inc. (ARDX): Elizabeth A Grammer , SVP, General Counsel of Ardelyx, Inc. sold 5,000 shares on Sep 22, 2016. The Insider selling transaction was reported by the company on Sep 26, 2016 to the Securities and Exchange Commission. The shares were sold at $12.00 per share for a total value of $60,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 21, 2016, Elizabeth A Grammer (SVP, General Counsel) sold 6,859 shares at $11.21 per share price.On Jul 20, 2016, Harry R Weller (10% owner) purchased 1,527,301 shares at $8.73 per share price.Also, On Jul 20, 2016, Ravi Viswanathan (10% owner) purchased 1,527,301 shares at $8.73 per share price.On Jul 20, 2016, Peter W. Sonsini (10% owner) purchased 1,527,301 shares at $8.73 per share price.
Shares of Ardelyx Inc (ARDX) ended Thursday, Sep 22, 2016 session in red amid volatile trading. The shares closed down -0.14 points or -1.17% at $11.83 with 1,17,037 shares getting traded. Post opening the session at $12, the shares hit an intraday low of $11.41 and an intraday high of $12 and the price vacillated in this range throughout the day. The company has a market cap of $559 M and the number of outstanding shares has been calculated to be 4,72,50,496 shares. The 52-week high of Ardelyx Inc is $22.4799 and the 52-week low is $6.36.
Ardelyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery development and commercialization of minimally-systemic small molecule therapeutics that work exclusively in the gastrointestinal (GI) tract to treat cardio-renal GI and metabolic diseases. The Company utilizing its platform discovered and designed its lead product candidate tenapanor which in clinical studies has demonstrated the ability to improve the symptoms of constipation-predominant irritable bowel syndrome (IBS-C) and to reduce the absorption of both dietary sodium and phosphorus. The Company in collaboration with AstraZeneca has completed a Phase IIb clinical trial evaluating tenapanor in patients with IBS-C. It also has other product candidates under development such as RDX002 for the treatment of Hyperphosphatemia RDX009 for the treatment of IBD Short Bowel Syndrome and non-alcoholic steatohepatitis (NASH) and RDX013 for the treatment of hyperkalemia.